Humanscape 2.75/5 (1)


A Blockchain-based Patient Network
Humanscape is working to establish its namesake platform Humanscape, a decentralized patient network based on blockchains. Humanscape can provide practical help for patients to overcome their diseases through intellectual and emotional interaction with each other based on community activities.



Starts in
2 days
17 Aug 2018

Price in ICO1 USD = 100 HUM
CountryHong Kong SAR China
preICO start31 May 2018
preICO end31 Jul 2018
ICO start17 Aug 2018
ICO end31 Aug 2018

  • TEAM

Although all human beings are susceptible to diseases, we continuously repeat the process of recovering our health through medical treatments. However, some patients suffer from incurable diseases whose etiologies are uncertain, exact diagnoses are difficult, and as a result, complete recovery is not possible. These incurable diseases include chronic diseases contracted by a large number of patients but with no complete cure and the need for lifelong management, such as diabetes mellitus, hypertension, cardiovascular diseases and cancer, in addition to rare and incurable diseases contracted by a small number of patients with a relatively small volume of epidemics data. Chronic diseases are becoming a global challenge due to rapidly-progressing population aging, decline in physical activity and lifestyle changes such as increased intake of fat and beverages. According to the World Health Organization (WHO), chronic diseases are the leading causes of deaths worldwide. As of 2015, 40 million out of 56 million deaths were caused by chronic diseases, and in addition, 1.7 million patients were predicted to die before the age of 70. Moreover, more than one third of the world’s population simultaneously suffer from multiple chronic conditions, which constitutes significant threats to patients’ health and imposes enormous costs on society. Specifically, medical costs in patients with multiple chronic diseases have been shown to increase by around 80 percent up to 300 percent, depending on age, gender and health conditions. Meanwhile, “rare and incurable diseases” are defined differently in each country, but generally refer to diseases for which the exact number of patients are unknown because of their small number of patients and difficulty of diagnosis. As of 2016, the number of rare diseases registered on Orphanet, a portal for rare diseases, amounted to 6,084 and the worldwide population with rare diseases is estimated at 350 million. In Korea, the total number of rare diseases is estimated at around 2,000 and the affected population is calculated at 600,000. It is characteristic of incurable diseases that their symptoms are controllable by medication, lifestyle changes, operations, etc. but it is not possible to eradicate or treat the underlying causes. Although early diagnosis may allow the early completion of treatment, these diseases cause suffering to patients and their families due to the inadequacy of knowledge on the diseases, insufficient research development and support, and the consequent lack of awareness toward the need for self-care.

Patient-Generated Health Data, a clue to solution

Patient-Generated Health Data (hereinafter PGHD) refers to health-related data recorded and generated by patients outside hospitals. Due to the widespread penetration of smartphones and the growing familiarity of patients with smart devices, the collection of diverse PGHD has become easier through the utilization of online survey, mobile apps and wearable devices. PGHD is a component of health data alongside genetic and clinical data, and occupies more than 60 percent of health data with the ratio gradually increasing. Since the majority of a patient’s activities occur outside hospitals, information recorded at a clinical office is inevitably limited. Therefore, a growing importance is being placed on PGHD, as information directly collected from patients and directly produced by patients throughout their struggle against diseases. While PGHD has previously been regarded with less clinical value and interest compared to other types of information, it fills an information niche by complementing aspects that cannot be explained by existing medical data, and allows a more comprehensive understanding of patients’ health. An Accenture survey found that the number of consumers who participated in the collection of PGHD using mobile healthcare applications rose to 33 percent in 2016, up from 16 percent in 2014, which shows that the volume of PGHD collected will increase exponentially in the future. Therefore, PGHD, which includes information on patients’ health and diseases, can provide a clue to the solution for diseases that are currently incurable.


Hee-jeong Shin
Business Developement
Yong-hyun Kim
Business Developement
Tae-eun Kim
Business Developement
Byung-ha Kim
Software Engineer
Hyun-sub Choi
Software Engineer
Back-seoung Choi
Software Engineer
Jung-min Yeom
Software Engineer
Do-Young Jeong
Software Engineer
Ji-yoo Choi
Jung-won Lim
Jin Woong Cho
Operation Managing
In-nyoung Choi
UX/UI design
Myeong-jin Lee
UX/UI design


  • 1Q Company Incorporation - Seoul, Korea (team foundation : 2014)
    2Q Development and Launch of ‘Beautycare’, a mobile application for aftercare services
    3Q Angel Investment Promotion from ‘Mashup Angels’ (Taek-Kyung Lee, CEO and Founder of ‘Daum’)
    4Q Client Usage Agreement with ‘Dream Medical Group’ and ‘DA Plastic Surgery’

  • 1Q Development and Beta test of ‘Helen’, Mobile Medical Assistant
    2Q Official Launch of ‘Helen’
    3Q Follow-up Investment Promotion from ‘Magellan Technology Investment(VC)’
    4Q Acquisition of 10,000 PHR Data from ‘Beautycare’ and ‘Helen’
    Concept Building of ‘Humanscape’, a Health Information Ecosystem

  • 1Q Whitepaper publication Company Incorporation - Hongkong
    2Q ‘Humanscape’ MVP Development Begins Pre-sale 1st, 2nd and 3rd round
    3Q Main sale Test group(patients/health professionals) building Indonesia incorporation / Organization PoC
    4Q Exchange listing. MVP release. Alpha test. PoC with global pharmaceutical companies and Contract research institutes

  • 1Q Beta test closing. Soft launch (South Korea, Indonesia). Business model validation
    2Q Main launch (South Korea, Indonesia).


Price in ICO1 USD = 100 HUM
Investment Info
Tokens Distribution20% - Public Sale
20% - Private Sale
20% - Community Construction
20% - Team
15% - Business Development
5% - Advisors


Legal entity

Registered Address: Hong-kong

Prehistory of project

According to the roadmap, first activities for project were at Q1 2016.No prehistory of the project were found

Product or its MVP

No MVP were found at the moment

Blockchain experience

No Blockchain experience information were found


No Escrow information were found


Update 02/08/2018

ICO that might interest you


Email Subscription - Footer

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.